Stanford researchers have developed a human spleen organoid platform that models inflammation and autoimmune responses to bacterial peptidoglycans in a physiologically relevant human immune setting.
Stanford researchers have identified that increased oxidative stress is a key molecular signature of fatigue-based conditions including Long COVID and myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS).
Researchers at Stanford have developed a novel strategy to enhance vaccine efficacy using mRNA lipid nanoparticles (LNPs) encoding immunostimulatory cytokines.
The recognition of peptide-MHC (pMHC) complexes by T cells is the cornerstone of cellular immunity, enabling the elimination of infected or tumoral cells. pMHC can thus be leveraged as a detection tool for T cells.
Stanford scientists have identified tuberculosis (TB) epitopes preferentially recognized by T cells in patients who naturally resist or control TB infection. Targeting these epitopes for vaccine development could lead to effective vaccines for TB.
Stanford researchers have created a new strategy for collecting and integrating human microbiome, multi-omics, and immune cell activation data that reveals new insights into the roles of different bacterial strains in human health.
Researchers at Stanford have developed a nanoparticle-based platform to enhance activation of self-specific CD8+ T cells in the tumor microenvironment to fight cancer while minimizing toxic side effects.
Stanford inventors have developed a nanoparticle containing the toll-like receptor agonist (TLR7-NP) that elicits a potent anti-tumor immune response in multiple cancer types without inducing undesired systemic inflammation and toxicity.
Stanford researchers have developed a nanoparticle adjuvant with spatiotemporal controlled release of TLR7 agonist for broad protection against influenza or SARS-CoV-2.
A team of Stanford researchers have identified a set of biomarkers that could be used to recognize patients with age-related declines in their immune function.